Z Or Y Radical Contains A Nitrogen Atom Patents (Class 514/534)
  • Patent number: 10307379
    Abstract: A transdermal delivery system for systemic delivery of donepezil is described, where the system comprises an adhesive matrix drug reservoir layer comprised of a copolymer of acrylic acid/vinyl acetate, triethyl citrate, and donepezil base generated in situ by reaction of donepezil HCl and an alkaline salt. The system is provided for treatment of Alzheimer's disease, and achieves transdermal delivery of the therapeutic agent at steady state that is bioequivalent to administration of the therapeutic agent orally.
    Type: Grant
    Filed: April 19, 2018
    Date of Patent: June 4, 2019
    Assignee: Corium, Inc.
    Inventors: Eun Soo Lee, Amit K. Jain, Parminder Singh
  • Patent number: 10292935
    Abstract: The invention provides a controlled release oral solid formulation comprising (a) a controlled release component comprising core comprising levodopa and/or an ester of levodopa or salts thereof, wherein the core is coated with a layer of a muco-adhesive polymer and externally coated with a layer of an enteric coated polymer; and (b) a decarboxylase inhibitor component.
    Type: Grant
    Filed: April 6, 2016
    Date of Patent: May 21, 2019
    Assignee: Impax Laboratories, Inc.
    Inventors: Ann Hsu, Liang C. Dong, Amy Ding, Suneel Gupta
  • Patent number: 10245176
    Abstract: A device and method is provided for treating a person by providing controlled stimulation of a branch of the trigeminal nerve of the person to induce a dive reflex response in the person. A device for providing this treatment includes a stimulus component controllably operable to stimulate a branch of the trigeminal nerve of a person. The stimulus component can be a Peltier device configured to reduce the temperature of the person's face in proximity to a branch of the trigeminal nerve to induce the dive reflex. A controller controls activation of the stimulus component when it is desirable to induce the dive reflex response in the person. The controller can sense physiological and ambient conditions and can activate and deactivate the stimulus component in response to a condition falling within or outside a threshold value.
    Type: Grant
    Filed: April 26, 2016
    Date of Patent: April 2, 2019
    Inventor: David Smith
  • Patent number: 10213510
    Abstract: Compositions comprised of a delivery vehicle or delivery system and an active agent dispersed within the delivery vehicle or system, wherein the delivery vehicle or system contains a polyorthoester polymer and a polar aprotic solvent. Also disclosed are low viscosity delivery systems for administration of active agents. The low viscosity delivery systems have a polyorthoester polymer, a polar aprotic solvent and a solvent containing a triglyceride viscosity reducing agent. Compositions described include an amide- or anilide-type local anesthetic of the “caine” classification, and a non-steroidal anti-inflammatory drug (NSAID), along with related methods, e.g., for treatment of post-operative pain or for prophylactic treatment of pain. The compositions are suitable for delivery via, e.g., direct application and instillation, intradermal injection, subcutaneous injection, and nerve block (perineural).
    Type: Grant
    Filed: April 20, 2015
    Date of Patent: February 26, 2019
    Assignee: Heron Therapeutics, Inc.
    Inventors: Thomas B. Ottoboni, Lee Ann Lynn Girotti
  • Patent number: 9826759
    Abstract: A composition and method for an avenanthramide-enriched, oat-based product having improved health effects. The oat-based product includes an avenanthramide ingredient having avenanthramides 2c:2p:2f in ratios comprising at least one of 1:1:1 or 1:2:2. More particularly, the avenanthramide ingredient may be derived synthetically or recovered from processing raw oats into constituent oat fractions.
    Type: Grant
    Filed: May 21, 2014
    Date of Patent: November 28, 2017
    Assignee: The Quaker Oats Company
    Inventors: YiFang Chu, Jodee Johnson, Marianne O'Shea, Yuhui Shi
  • Patent number: 9820937
    Abstract: The invention described herein provides a fast dispersing oral solid dosage form containing monoamine oxidase B inhibitor (MAO-B inhibitor) as the active ingredient, and method of treating disease therewith, such as Parkinson's disease. In one embodiment, the monoamine oxidase B inhibitor selegiline or its analog can be the sole active ingredient in the composition administered. The dosage form composition is formulated to promote absorption through the buccal, sublingual, pharyngeal and/or esophageal mucous membrane tissue, such that at least 5% of the active ingredient is absorbed within one minute of placement in the oral cavity, as determined by a buccal absorption test. Monoamine oxidase B inhibitor compounds administered in accordance with the invention decrease the amount of undesirable metabolites associated with first pass effect of selegiline, for example, such as amphetamine and methamphetamine.
    Type: Grant
    Filed: May 18, 2010
    Date of Patent: November 21, 2017
    Assignee: R.P. Scherer Technologies, LLC
    Inventors: Francesca Mary Brewer, Edward Stewart Johnson, Anthony Clarke
  • Patent number: 9522880
    Abstract: Compounds and methods for use in detecting gabapentin in a sample suspected of containing gabapentin are disclosed. Gabapentin derivatives are used to produce gabapentin conjugates. A gabapentin-immunogenic carrier conjugate may be used as an immunogen for the preparation of an anti-gabapentin antibody. A gabapentin-detectable label may be used in a signal producing system in gabapentin assays.
    Type: Grant
    Filed: July 30, 2014
    Date of Patent: December 20, 2016
    Assignee: ARK Diagnostics, Inc.
    Inventors: Johnny Jose Valdez, Byung Sook Moon, Michael Kevin Helms, Alejandro A. Orozco
  • Patent number: 9428549
    Abstract: The present invention relates to derivatives of N-urea substituted amino acids, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide 2 receptor.
    Type: Grant
    Filed: July 10, 2014
    Date of Patent: August 30, 2016
    Assignee: Allegran, Inc.
    Inventors: Richard L. Beard, Tien T. Duong, John E. Donello, Veena Viswanath, Michael E. Garst
  • Patent number: 9308181
    Abstract: The present disclosure is drawn to topical formulations, transdermal systems, and related methods. In one embodiment, a topical formulation is provided that includes a local anesthetic, a first compound, and a second compound. The first compound and second compound are different and each is selected from the group consisting of N-lauroyl sarcosine, sodium octyl sulfate, methyl laurate, isopropyl myristate, oleic acid, glyceryl oleate, and sodium lauryl sulfoacetate.
    Type: Grant
    Filed: March 8, 2013
    Date of Patent: April 12, 2016
    Assignee: Nuvo Research Inc.
    Inventors: Edward T. Kisak, John M. Newsam, Dominic King-Smith, Pankaj Karande, Samir Mitragotri, Tejas Desai, Wade A. Hull
  • Patent number: 9084763
    Abstract: A method of treating tachycardia while minimizing and/or controlling hypotension associated with such treatment includes administering a therapeutically effective amount of a pharmaceutical composition comprising the S-isomer of esmolol to a subject in need thereof.
    Type: Grant
    Filed: November 8, 2013
    Date of Patent: July 21, 2015
    Assignees: BAXTER INTERNATIONAL INC., BAXTER HEALTHCARE SA
    Inventors: Barrett Rabinow, Jeff McKee
  • Patent number: 9023891
    Abstract: Synergistic antimicrobial compositions are provided by combining effective amounts of N?-long chain alkanoyl di basic amino acid alkyl ester salts with glycerol monofatty acid esters resulting more effective anti-microbials and food preservatives.
    Type: Grant
    Filed: May 7, 2012
    Date of Patent: May 5, 2015
    Assignee: Nevada Naturals, Inc.
    Inventors: Richard F. Stockel, Anthony J. Sawyer
  • Patent number: 8980290
    Abstract: The present invention relates generally to compositions or formulations for transdermal or transmucosal administration of anticholinergic agents such as oxybutynin. The invention utilizes a novel delivery vehicle and is a substantially malodorous-free and irritation free transdermal formulation which is substantially free of long chain fatty alcohols, long-chain fatty acids, and long-chain fatty esters. A method is disclosed for treating a subject for urinary incontinence with these formulations while reducing the incidences of peak concentrations of drug and undesirable side effects associated with oral anticholinergics.
    Type: Grant
    Filed: November 6, 2009
    Date of Patent: March 17, 2015
    Assignee: Antares Pharma IPL AG
    Inventors: Dario Norberto R. Carrara, Arnaud Grenier
  • Publication number: 20150057316
    Abstract: The present description relates to compounds of Formula I (A+ X?), a diastereoisomer, an enantiomer, or a mixture thereof, pharmaceutical composition comprising same and uses thereof for gastrointestinal endoscopic and medical imaging applications, and for the treatment of visceral pain: Where R1 and R2 are as defined herein
    Type: Application
    Filed: March 11, 2013
    Publication date: February 26, 2015
    Inventors: Jean-Francois Meunier, Cheuk Kun Lau, Daniel Guay, Gregory Bydlinski, Nadejda Spassova, Louis-David Cantin, Maxime Ranger
  • Patent number: 8946290
    Abstract: Active compound combinations of compounds of group A, particularly opioids such as (+)-(2R,3R)-1-dimethylamino-3-(3-methoxy-phenyl)-2-methyl-pentan-3-ol or a salt thereof with a physiologically tolerated acid, and compounds of group B, particularly anti-muscarine agents such as oxybutynin or a salt thereof with a physiologically tolerated acid suitable for treatment of an increased urge to urinate or urinary incontinence. Related pharmaceutical formulations and methods of treatment of an increased urge to urinate or urinary incontinence are also provided.
    Type: Grant
    Filed: September 23, 2011
    Date of Patent: February 3, 2015
    Assignee: Gruenenthal GmbH
    Inventor: Thomas Christoph
  • Publication number: 20140357713
    Abstract: The present disclosure provides antimicrobial compounds, compositions comprising such antimicrobial compounds, and methods of their use, in particular, antibacterial compounds and antifungal compounds. In certain aspects, the antimicrobial compounds are effective against pathogens of hospital-acquired infections. In certain aspects, the antimicrobial compounds are effective against pathogens that are resistant to antibiotics. The antimicrobial compounds can be used in antibacterial compositions, antifungal compositions, antiseptic compositions and disinfectant compositions. The antimicrobial compounds can be used as adjuncts in antibacterial compositions and antifungal compositions.
    Type: Application
    Filed: May 7, 2014
    Publication date: December 4, 2014
    Applicant: NexMed Holdings, Inc.
    Inventors: Bassam B. Damaj, Richard Martin
  • Publication number: 20140336137
    Abstract: The invention relates to nitroso derivatives including carboxylic acid and phosphoric acid esters of hydroxy nitroso compounds that donate nitroxyl (HNO) under physiological conditions. The compounds and compositions of the invention are useful in treating and/or preventing the onset and/or development of diseases or conditions that are responsive to nitroxyl therapy, including heart failure, ischemia/reperfusion injury and cancer.
    Type: Application
    Filed: July 28, 2014
    Publication date: November 13, 2014
    Inventors: Lisa Marie Frost, Stephen Martin Courtney, Frederick Arthur Brookfield, Vincent Jacob Kalish
  • Publication number: 20140315960
    Abstract: The present invention relates to novel depot formulations (prodrugs) comprising an immobility promoting unit linked via an ester to an active pharmaceutical ingredient, i.a. common NSAIDs. The novel depot formulations are suitable for intra-articular injections and are soluble at slightly acidic pH to facilitate ease of injection, and sparingly soluble at physiological pH thereby precipitating at the site of administration. The precipitate will slowly dissolve and the active drug is released from dissolved depot formulation following esterase mediated cleavage of the ester link between the immobility promoting unit and the active pharmaceutical agent.
    Type: Application
    Filed: October 31, 2012
    Publication date: October 23, 2014
    Inventor: Claus Selch LARSEN
  • Publication number: 20140308361
    Abstract: The composition for management of periodontal diseases includes a gel matrix having a polymer system and a plurality of microspheres dispersed in the polymer system. The polymer system contains about one-half a dose of medicament, while the micro spheres contain the remainder. Upon administration of the composition into the periodontal cavity, the medicament in the polymer system provides an initial therapeutic benefit, while the remainder of the medication is released over time via degradation of the microspheres. This biphasic pattern of medicament delivery provides increased efficacy of the medicament through sustained delivery of the same.
    Type: Application
    Filed: June 27, 2014
    Publication date: October 16, 2014
    Inventors: NOHA MOHAMED ZAKI RAYAD, Ibrahim Maghrabi, Mohamed Mostafa Hafez Mahmoud
  • Publication number: 20140296241
    Abstract: The disclosure provides pharmaceutical preparations containing (2R,6R)-hydroxynorketamine, or (R)- or (S)-dehydronorketamine, or other stereoisomeric dehydro or hydroxylated ketamine metabolite. (2R,6R)-hydroxynorketamine The disclosure also provides novel ketamine metabolite prodrugs. The disclosure provides methods of treating, bipolar depression, major depressive disorder, neuropathic and chronic pain, including complex regional pain disorder (CRPS) by administering a purified ketamine metabolite or a ketamine metabolite prodrug directly to patients in need of such treatment.
    Type: Application
    Filed: October 15, 2012
    Publication date: October 2, 2014
    Inventors: Irving W. Wainer, Ruin Moaddel, Michel Bernier, Carlos A. Zarate, Marc C. Torjman, Michael E. Goldberg, Mary J. Tanga
  • Publication number: 20140256666
    Abstract: The present invention describes single drug entities, formed by connecting an antibiotic moiety via a linker with a non-steroidal anti-inflammatory drug (NSAID) moiety. Upon topical application to the eye, the conjugate hybrid would undergo enzymatic and/or hydrolytic cleavage to release the individual antibiotic and NSAID drug.
    Type: Application
    Filed: March 6, 2014
    Publication date: September 11, 2014
    Applicant: Allergan, Inc.
    Inventors: Santosh C. Sinha, Smita S. Bhat, Ken Chow, LIMING WANG, MICHAEL E. GARST, MAYSSA ATTAR, BRANDON D. SWIFT
  • Patent number: 8829047
    Abstract: A pharmaceutical composition comprising (S)-methyl-3-[4-(2-hydroxy-3-isopropylamino)propoxy]phenylpropionate in a concentration between about 75 mM and about 150 mM, which is substantially free of the R-isomer or pharmaceutically acceptable salt thereof, is provided. A method of treating a cardiac disorder is also provided and includes administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising (S)-methyl-3-[4-(2-hydroxy-3-isopropylamino)propoxy]phenylpropionate hydrochloride, wherein the (S)-methyl-3-[4-(2-hydroxy-3-isopropylamino)propoxy]phenylpropionate hydrochloride is present at a concentration between about 75 mM and about 150 mM and wherein the pharmaceutical composition is substantially free of (R)-methyl-3-[4-(2-hydroxy-3-isopropylamino)propoxy]phenylpropionate or pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: January 26, 2012
    Date of Patent: September 9, 2014
    Assignees: Baxter International Inc., Baxter Healthcare SA
    Inventors: Jerome H. Gass, Jeff McKee, Barrett Rabinow
  • Publication number: 20140242139
    Abstract: A medical device for placement in a body of a mammal is provided. The medical device comprises (1) a polymeric matrix forming the device and defining a lumen through the device, the matrix comprising polymer macromolecules and defining spaces between the polymer macromolecules; (2) a drug contained within at least some of the spaces of the matrix; and (3) a material contained within at least some of the spaces of the matrix to affect diffusion of the drug out of the polymeric matrix when the medical device is placed in the body of the mammal.
    Type: Application
    Filed: February 26, 2014
    Publication date: August 28, 2014
    Applicant: Boston Scientific Scimed, Inc.
    Inventors: Jianmin Li, Weenna Bucay-Couto
  • Patent number: 8815948
    Abstract: An alternative method of delivery of homeopathic medicines by targeting delivery to the MALT's, especially of the intestinal tract and in high volumes.
    Type: Grant
    Filed: February 10, 2005
    Date of Patent: August 26, 2014
    Inventors: Char Tara Albert, Floyd E. Taub
  • Publication number: 20140234428
    Abstract: The invention, a transdermal delivery method, relates to penetration-enhancing pharmaceutical compositions comprising a novel, stable mixture of cetylated esters, cetyl or stearyl alcohols, polar solvents and surfactants, which, under appropriate conditions, combine into amphiphilic nanoparticles within a stabilized liquid dispersion for use in delivery of medicinal agents through the skin. The term cetosomes is used to describe these particles in order to differentiate them from other nanoparticles, such as niosomes, cerasomes, polymeric micelles, dendrimers, liposomes, lipoids, solid lipid nanoparticles and other particles. The self-assembling cetosomes, with both ionic and nonionic points of attraction, incorporate and concentrate a variety of different bioactive agents of interest and demonstrate stable properties with similarities to colloidal molecular structures. The compositions enhance topical transdermal fluxes of bioactives without permanently disrupting natural skin barrier function.
    Type: Application
    Filed: February 15, 2013
    Publication date: August 21, 2014
    Applicant: Cymbiotics, Inc.
    Inventors: Raj R. Barathur, Jack Bain Bookout
  • Publication number: 20140213552
    Abstract: The present application provides novel compounds and methods for preparing and using these compounds. These compounds are useful in treating pain, itch, overactive bladder and/or interstitial cystitis in patients by administering one or more of the compounds to a patient. The methods include administering a compound of formula (I) and a TRPV1 receptor activator. In one embodiment, the TRPV1 receptor activator is lidocaine.
    Type: Application
    Filed: March 20, 2014
    Publication date: July 31, 2014
    Applicant: Endo Pharmaceuticals Inc.
    Inventors: Scott Kevin Thompson, Roger Astbury Smith, Sandeep Gupta, Tony Priestley, Nicholas James Laping, Ashis K. Saha, Sonali Rudra
  • Publication number: 20140194416
    Abstract: The invention relates to N-hydroxylsulfonamide derivatives that donate nitroxyl (HNO) under physiological conditions and are useful in treating and/or preventing the onset and/or development of diseases or conditions that are responsive to nitroxyl therapy, including heart failure and ischemia/reperfusion injury. Novel N-hydroxylsulfonamide derivatives release NHO at a controlled rate under physiological conditions, and the rate of HNO release is modulated by varying the nature and location of functional groups on the N-hydroxylsulfonamide derivatives.
    Type: Application
    Filed: March 11, 2014
    Publication date: July 10, 2014
    Applicants: Cardioxyl Pharmaceuticals, Inc., The Johns Hopkins University
    Inventors: John P. Toscano, Frederick Arthur Brookfield, Andrew D. Cohen, Stephen Martin Courtney, Lisa Marie Frost, Vincent Jacob Kalish
  • Publication number: 20140187617
    Abstract: Provided are compounds that are inhibitors of both rho kinase and of a monoamine transporter (MAT) act to improve the disease state or condition. Further provided are compositions comprising the compounds. Further provided are methods for treating diseases or conditions, the methods comprising administering compounds according to the invention. One such disease may be glaucoma for which, among other beneficial effects, a marked reduction in intraocular pressure (IOP) may be achieved.
    Type: Application
    Filed: December 23, 2013
    Publication date: July 3, 2014
    Applicant: AERIE PHARMACEUTICALS, INC.
    Inventors: Mitchell A. deLong, Jill Marie Sturdivant, Susan M. Royalty
  • Publication number: 20140186428
    Abstract: A method for producing a patch comprising a support layer and an adhesive agent layer arranged on at least one surface of the support layer, the method comprising: a step A of obtaining an adhesive agent layer composition comprising oxybutynin hydrochloride as a drug, an acrylic-based polymer and/or a rubber-based polymer as an adhesive base agent, liquid paraffin, a sterol, an organic acid, and a tackifier; a step B of heating the adhesive agent layer composition at a temperature in a range from 55 to 70° C. for 1 to 24 hours; and a step C of cooling the heated adhesive agent layer composition to a temperature lower than room temperature at an average rate of temperature drop of 1 to 20° C./hour, thereby obtaining the adhesive agent layer comprising the drug at a supersaturated concentration in a dissolved form.
    Type: Application
    Filed: June 21, 2013
    Publication date: July 3, 2014
    Inventors: Kazunosuke AIDA, Terumitsu KAIHO, Tetsurou TATEISHI, Nobuo TSUTSUMI
  • Publication number: 20140161865
    Abstract: A method for producing a patch having a high skin penetrability and a high pharmaceutical physical properties such as adhesion and cohesiveness, and a long-term storability. The patch is produced by first obtaining an adhesive agent layer composition containing oxybutynin and/or salt thereof as a drug, an acrylic-based polymer and/or a rubber-based polymer as an adhesive base agent, liquid paraffin, an organic acid, and a tackifier; heating the adhesive agent layer composition at a temperature in a range from a melting point of the drug to a temperature higher than the melting point by 10° C. for 2 to 24 hours; and slowly cooling the heated adhesive agent layer composition to obtain the adhesive agent layer comprising the drug at a supersaturated concentration in a dissolved form.
    Type: Application
    Filed: February 21, 2013
    Publication date: June 12, 2014
    Applicant: HISAMITSU PHARMACEUTICAL CO., INC.
    Inventors: Naruhito Higo, Tetsurou Tateishi, Takaaki Terahara, Kazunosuke Aida, Shigeki Hayashi, Nobuo Tsutsumi
  • Patent number: 8748488
    Abstract: Administration of Oxybutynin directly to a patient's lungs for treating urinary incontinence, respiratory disease or IBD.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: June 10, 2014
    Assignee: Microdose Therapeutx, Inc.
    Inventors: Michael J. Martin, Alan B. Watts, Robert Cook
  • Patent number: 8741952
    Abstract: The present disclosure relates to polymorphs of 4-[2-dimethylamino-1-(1-hydroxycyclohexyl)ethyl]phenyl 4-methylbenzoate hydrochloride, methods for preparing the same and use of the same.
    Type: Grant
    Filed: March 18, 2013
    Date of Patent: June 3, 2014
    Assignees: Shangong Luye Pharmaceutical Co., Ltd.
    Inventors: Youxin Li, Wanhui Liu, Yang Lv, Guanhua Du, Qingguo Meng, Mina Yang, Fengmei Zhou, Ju Li, Xuemei Zhang
  • Publication number: 20140135392
    Abstract: The present invention provides safe and effective methods for the treatment of sialorrhea (excessive drooling) by administering an effective amount of N-desethyloxybutynin, or an optical R- or S-isomer thereof. N-desethyloxybutynin is a metabolite of oxybutynin and has higher affinity for receptors present in the parotid glands (the salivary glands in humans) than oxybutynin.
    Type: Application
    Filed: November 13, 2012
    Publication date: May 15, 2014
    Applicant: NeuRx Pharmaceuticals LLC
    Inventor: Dinesh C. Patel
  • Publication number: 20140128439
    Abstract: Methods of treating gout flares comprising administering a composition comprising a first urate-lowering agent are disclosed. In some aspects, the first urate-lowering agent is (?)-halofenate, (?)-halofenic acid, or a pharmaceutically acceptable salt thereof. Other aspects provide for methods of reducing the number, duration, frequency or intensity of gout flares experienced by a subject.
    Type: Application
    Filed: August 7, 2013
    Publication date: May 8, 2014
    Applicant: Metabolex, Inc.
    Inventors: Brian Edward Lavan, Gopal Chandra Saha, Brian K. Roberts, Charles A. McWerther
  • Publication number: 20140128438
    Abstract: Methods of treating gout flares comprising administering a composition comprising a first urate-lowering agent are disclosed. In some aspects, the first urate-lowering agent is (?)-halofenate, (?)-halofenic acid, or a pharmaceutically acceptable salt thereof. Other aspects provide for methods of reducing the number, duration, frequency or intensity of gout flares experienced by a subject.
    Type: Application
    Filed: November 2, 2012
    Publication date: May 8, 2014
    Inventors: Brian Edward Lavan, Gopal Chandra Saha, Charles A. McWherter, Brian K. Roberts
  • Patent number: 8703184
    Abstract: Methods and compositions for reducing the frequency of urination are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising an analgesic agent formulated in a delayed-release formulation. Another method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising multiple active ingredients. Yet another method comprises administering to a subject in need thereof an effective amount of a diuretic followed with another administration of a pharmaceutical composition comprising an analgesic agent.
    Type: Grant
    Filed: March 20, 2013
    Date of Patent: April 22, 2014
    Assignee: Wellesley Pharmaceuticals, LLC
    Inventor: David A. Dill
  • Patent number: 8685453
    Abstract: Methods and compositions for reducing the frequency of urination are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising an analgesic agent formulated in an extended-release formulation. Another method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising multiple active ingredients formulated for extended-release. Yet another method comprises administering to a subject in need thereof an effective amount of a diuretic followed with another administration of a pharmaceutical composition comprising an analgesic agent formulated for extended-release.
    Type: Grant
    Filed: March 20, 2013
    Date of Patent: April 1, 2014
    Assignee: Wellesley Pharmaceuticals, LLC
    Inventor: David A. Dill
  • Publication number: 20140051751
    Abstract: Environmentally-friendly alternatives to organometallic antifoulants that are efficacious at preventing biofouling by organisms such as the zebra mussel. Preferred antifoulant compositions utilize compounds having a Lipophilic-Amide-Spacer-ElectroNegative (“LASEN”) structural motif, such as capsaicin, and compounds having a TetraHydroCannibinoid (“THC”) structural motif. The antifoulant compositions are non-toxic, and effective.
    Type: Application
    Filed: October 25, 2013
    Publication date: February 20, 2014
    Applicants: The Board of Regents of the University of Texas System, University of North Texas Health Science Center at Fort Worth
    Inventors: John A. Schetz, Robert F. McMahon
  • Patent number: 8652491
    Abstract: The present invention relates generally to compositions or formulations for transdermal or transmucosal administration of anti-cholinergic agents such as oxybutynin. The invention utilizes a novel delivery vehicle and is a substantially malodorous-free and irritation free transdermal formulation which is substantially free of long chain fatty alcohols, long-chain fatty acids, and long-chain fatty esters. A method is disclosed for administering such formulations to a person in need thereof while reducing the incidences of peak concentrations of drug and undesirable side effects associated with oral anti-cholinergics.
    Type: Grant
    Filed: August 3, 2012
    Date of Patent: February 18, 2014
    Assignee: Antares Pharma IPL AG
    Inventors: Dario Norberto R. Carrara, Arnaud Grenier
  • Publication number: 20140037710
    Abstract: A method for producing a patch including a support layer and an adhesive layer, comprising the step of forming the adhesive layer with use of an adhesive layer composition obtained by mixing an alkali metal diacetate, a drug, and a nonaqueous adhesive base such that the molar ratio between the drug and the alkali metal diacetate (the number of moles of the drug:the number of moles of the alkali metal diacetate) is from 1:0.5 to 1:15.
    Type: Application
    Filed: April 12, 2012
    Publication date: February 6, 2014
    Applicant: HISAMITSU PHARMACEUTICAL CO., INC.
    Inventors: Eiji Hashimoto, Isao Hagiwara, Yukihisa Naka, Hideharu Chono
  • Publication number: 20130324555
    Abstract: The present invention is directed to the method of use of effective pharmaceutical formulations for the treatment of diseases caused by apicomplexan parasites, said formulation comprised of a salicylanilide or salicylanilide derivative, disclosed herein, alone or in combination with one or more other active or excipient pharmaceutical substances. The present invention is further directed to the method of use of effective pharmaceutical formulations for the treatment of diseases caused by apicomplexan parasites, said formulation comprised of a combination of salicylanilides or salicylanilide derivatives, disclosed herein. The present invention is further directed to the method of use of effective pharmaceutical formulations for the treatment of diseases caused by apicomplexan parasites, said formulation comprised of a combination of salicylanilides or salicylanilide derivatives, disclosed herein, further comprised of one or more active or excipient pharmaceutical substances.
    Type: Application
    Filed: May 29, 2013
    Publication date: December 5, 2013
    Inventors: Richard Delarey Wood, Rima McLeod, Ernest Mui, Alina Fomovska, William Welsh
  • Patent number: 8592438
    Abstract: A plant disease control composition comprising, as an active ingredient, a compound of formula (I) or a salt thereof, and one or more anilinopyrimidine compounds selected from the group consisting of 4,6-dimethyl-N-phenyl-2-pyrimidinamine, 4-methyl-N-phenyl-6-(1-propynyl)-2-pyrimidinamine and 4-cyclopropyl-6-methyl-N-phenyl-2-pyrimidinamine has an excellent plant disease control effect.
    Type: Grant
    Filed: March 16, 2009
    Date of Patent: November 26, 2013
    Assignee: Sumitomo Chemical Intellectual Property Service, Ltd
    Inventors: Masanao Takaishi, Norio Kimura
  • Publication number: 20130302305
    Abstract: The present application discloses a method of lowering serum uric acid level in a subject with impaired renal function, comprising administering to the subject a compound of Formula (I), as disclosed herein.
    Type: Application
    Filed: November 2, 2012
    Publication date: November 14, 2013
    Inventors: Gopal Chandra Saha, Brian K. Roberts, Brian Edward Lavan, Charles A. McWherter
  • Publication number: 20130303437
    Abstract: The disclosure provides a molecular genetic approach of targeted mutagenesis and heterologous expression, coupled with in vitro and in vivo models of bacterial pathogenesis, to demonstrate that the S. aureus pigment is a virulence factor and potential novel target for antimicrobial therapy.
    Type: Application
    Filed: July 16, 2013
    Publication date: November 14, 2013
    Inventors: Victor NIZET, George Y. LIU
  • Patent number: 8575214
    Abstract: The present invention provides novel mGlu2/3 agonists of the formula wherein R1, R2, and R3 are as defined herein, for use in the treatment of neurological or psychiatric disorders.
    Type: Grant
    Filed: January 29, 2013
    Date of Patent: November 5, 2013
    Assignee: Eli Lilly and Company
    Inventors: Stephen Richard Baker, Christopher David Beadle, Barry Peter Clark, James Allen Monn, Lourdes Prieto
  • Publication number: 20130281531
    Abstract: The present disclosure relates to polymorphs of 4-[2-dimethylamino-1-(1-hydroxycyclohexyl)ethyl]phenyl 4-methylbenzoate hydrochloride, methods for preparing the same and use of the same.
    Type: Application
    Filed: March 18, 2013
    Publication date: October 24, 2013
    Inventors: Shandong Luye Pharmaceutical Co., Ltd., Youxin Li
  • Publication number: 20130274331
    Abstract: Disclosed herein are pharmaceutical compositions, methods and kits for lowering the serum uric acid level of a subject and for the treatment of a condition associated with elevated serum uric acid levels comprising administering a composition comprising a urate-lowering agent and an anti-inflammatory agent. In some aspects the urate-lowering agent is (?)-halofenate, (?)-halofenic acid, or a pharmaceutically acceptable salts thereof. In some aspects the second agent is an anti-inflammatory agent, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: April 12, 2013
    Publication date: October 17, 2013
    Inventors: Gopal Chandra Saha, Brian Edward Lavan, Brian K. Roberts, Charles A. McWherter
  • Publication number: 20130267593
    Abstract: Administration of Oxybutynin directly to a patient's lungs for treating urinary incontinence, respiratory disease or IBD.
    Type: Application
    Filed: March 14, 2013
    Publication date: October 10, 2013
    Applicant: MICRODOSE THERAPEUTX, INC.
    Inventors: Michael J. Martin, Alan B. Watts, Robert Cook
  • Patent number: 8552060
    Abstract: This invention is directed to a method of treating sexual dysfunction in a subject, comprising the step of administering a therapeutically effective amount of a compound of Formula (I): or a pharmaceutically acceptable salt or ester thereof wherein Rx is a member selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, halogen selected from F, CI, Br and I, alkoxy containing 1 to 3 carbon atoms, nitro, hydroxy, trifluoromethyl, and thioalkoxy containing 1 to 3 carbon atoms; x is an integer of 1 to 3, with the proviso that R may be the same or different when x is 2 or 3; R1 and R2 can be the same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, aryl, arylalkyl, cycloalkyl of 3 to 7 carbon atoms; R1 and R2 can be joined to form a 5 to 7-membered heterocycle substituted with a member selected from the group consisting of hydrogen, alkyl, and aryl groups, wherein the cyclic compound can comprise 1 to 2
    Type: Grant
    Filed: June 13, 2006
    Date of Patent: October 8, 2013
    Assignee: SK Biopharmaceuticals Co., Ltd.
    Inventors: Joseph Palumbo, Jonathan Sporn, Thomas Steckler, Yong Choi, James S. Lee
  • Publication number: 20130230542
    Abstract: Provided are compounds according to the following Formula I: The Formula I compounds are activated in the presence of reactive oxygen species (ROS) and are therefore selective anti-cancer therapeutics for cancers associated with elevated ROS. Also provided are methods and pharmaceutical compositions for treating cancers associated with increased ROS.
    Type: Application
    Filed: March 1, 2013
    Publication date: September 5, 2013
    Applicants: CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER, UNIVERSITY OF CINCINNATI
    Inventors: Edward J. Merino, James C. Mulloy, Guorui Li, Tiffany Bell-Horwath
  • Patent number: RE46555
    Abstract: The present invention concerns deuterated catecholamine derivatives as well as pharmaceuticals containing these compounds. In addition, the invention concerns the use of deuterated catecholamine derivatives as well as physiologically acceptable salts thereof, and also pharmaceutical compositions, which contain these compounds, also in combination with enzyme inhibitors, for the treatment of dopamine deficiency diseases or diseases which are based on disrupted tyrosine transport or disrupted tyrosine decarboxylase, as well as other disorders.
    Type: Grant
    Filed: August 20, 2014
    Date of Patent: September 19, 2017
    Assignee: Teva Pharmaceuticals International GmbH
    Inventors: Rudolf-Giesbert Alken, Frank Schneider